Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Matthew Mossanen MD, MPH

Matthew Mossanen MD, MPH

Assistant Professor of Surgery, Harvard Medical School, Brigham and Women's Hospital, Division of Urology, Boston, Massachusetts

Dr. Mossanen is a graduate of the University of California, Los Angeles (UCLA) in Los Angeles, CA and he received his medical degree from the David Geffen School of Medicine at UCLA. He also holds a Master of Public Health from the Harvard T.H. Chan School of Public Health in Boston, MA. Dr. Mossanen completed a residency in Urology from the University of Washington in Seattle, WA followed by a fellowship in Urologic Oncology in the Combined Harvard Urologic Oncology Fellowship at Massachusetts General Hospital and Brigham and Women’s Hospital. Dr. Mossanen has been board certified by the American Board of Urology since 2020.

His research and clinical interests include: bladder cancer, kidney cancer, kidney masses/cysts, laparoscopic surgery, penile cancer, prostate cancer, robotic surgery, testicular cancer

Recent Contributions to PracticeUpdate:

  1. 2022 Top Story in Bladder Cancer: Use of N-803 With BCG in BCG-Unresponsive Non–Muscle Invasive Bladder Cancer
  2. ESMO 2022: Recommendations From Dr. Matthew Mossanen for Bladder Cancer
  3. ASCO 2022: Abstract Recommendations From Dr. Matthew Mossanen for Bladder Cancer
  4. 2021 Top Story in Bladder Cancer: Pembrolizumab Monotherapy for BCG-Unresponsive Carcinoma
  5. EAU Guidelines on Non–Muscle-Invasive Bladder Cancer
  6. ESMO 2021: Recommendations From Dr. Matthew Mossanen for Urothelial Carcinoma
  7. The Impact of Smoking on Outcomes After Radical Cystectomy for Bladder Cancer
  8. Impact of Neoadjuvant Chemotherapy on Bladder Cancer Outcomes
  9. An Overview of Risk Factors for Bladder Cancer
  10. Gemcitabine, Cisplatin, and Nivolumab With Selective Bladder Sparing in Muscle-Invasive Cancer

Most Read This Week

Recently Updated